CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
At the AACC show 2015
Diadexus and Mayo Clinic signed an agreement to collaborate in the areas of education, research, and innovation on the PLAC Test for Lp-PLA2 Activity. The FDA-cleared test is used to identify risk for coronary heart disease in patients with no history of cardiovascular events.
As part of the agreement, Mayo Clinic’s Department of Laboratory Medicine and Pathology will participate in the Diadexus Laboratory Partnership Program, in which Diadexus will provide educational support during the integration and use of Lp-PLA2 Activity testing in clinical practice. Once fully integrated, the test will be available to patients and providers through Mayo Medical Laboratories.
Diadexus, 650-246-6400